Related Experiment Video
Updated: May 14, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Controlled release of simvastatin from biomimetic β-TCP drug delivery system
Joshua Chou1, Tomoko Ito, David Bishop
1Advanced Tissue Regeneration and Drug Delivery Group, School of Medical and Molecular Sciences, University of Technology Sydney, Sydney, New South Wales, Australia. Joshua.chou@uts.edu.au
Abstract:
Simvastatin have been shown to induce bone formation and there is currently a urgent need to develop an appropriate delivery system to sustain the release of the drug to increase therapeutic efficacy whilst reducing side effects. In this study, a novel drug delivery system for simvastatin by means of hydrothermally converting marine exoskeletons to biocompatible beta-tricalcium phosphate was investigated. Furthermore, the release of simvastatin was controlled by the addition of an outer apatite coating layer. The samples were characterized by x-ray diffraction analysis, fourier transform infrared spectroscopy, scanning electron microscopy and mass spectroscopy confirming the conversion process. The in-vitro dissolution of key chemical compositional elements and the release of simvastatin were measured in simulated body fluid solution showing controlled release with reduction of approximately 25% compared with un-coated samples. This study shows the potential applications of marine structures as a drug delivery system for simvastatin.
Related Concept Videos
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Overview
Modified-Release Drug Delivery Systems: Bioavailability

